Continuing Pharmacy Education / CE Master List / Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block-RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Describe the unique mechanisms of action of xanomeline-trospium in the management of schizophrenia and dextromethorphan-containing medications in the management of major depressive disorder
  • Distinguish between adverse effect profiles of new psychiatric medications compared to traditional antipsychotics and antidepressants
  • Identify appropriate candidates for new psychiatric medications based on knowledge of efficacy, safety, and patient-specific factors

 

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-068-H01-P

Session Code

25RW68-PBJ53

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.  Don't forget to use the session code above, or that was sent to you in your confirmation email NOT the one on the presentation!

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-068-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Kristin Waters, PharmD, BCPS, BCPP
Assistant Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Waters is on the Johnson and Johnson speakers' bureau, but the information discussed here has no overlap. All financial relationships with ineligible companies have been mitigated.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Download

Post Test

NKOTB: Breaking the Mold: Novel Mechanisms in Psychiatry’s New Kids on the Block Assessment Questions

25-068

    Posttest

    1. What is the purpose of pairing trospium with xanomeline in the combination drug used in the management of schizophrenia?
        1. Trospium reduces the amount of weight gain associated with xanomeline.
        2. Trospium effectively treats the cognitive symptoms associated with schizophrenia.
        3. Trospium reduces the amount of gastrointestinal adverse effects associated with xanomeline.
    2. Compared with standard antipsychotic medications, xanomeline/trospium is associated with less:
        1. Weight gain
        2. Constipation
        3. Hypertension
    3. Which of the following patients would be the best candidate for treatment with xanomeline/trospium?
        1. A patient with newly diagnosed schizophrenia who has never been treated with an antipsychotic.
        2. A patient with schizophrenia who has developed significant movement-related adverse effects during treatment with risperidone.
        3. A patient with schizophrenia who prefers treatment with long-acting injectable medications due to problems remembering to take oral medications.
    4. The mechanism of action of dextromethorphan is different from other medications used to manage depression because it antagonizes which receptor type?
        1. Serotonin
        2. NMDA
        3. Glutamate
    5. Which of the following is a common adverse effect associated with dextromethorphan/bupropion?
        1. Dizziness
        2. Sexual dysfunction
        3. Weight gain
    6. Which of the following patients would be the best candidate for treatment with dextromethorphan/bupropion?
        1. A patient with major depressive disorder and epilepsy who was previously treated with fluoxetine.
        2. A patient with major depressive disorder who has had seven previous antidepressant trials that were not effective.
        3. A patient with major depressive disorder and diabetes mellitus type 2 who has had previous trials with escitalopram and venlafaxine.

    VIDEO